title: [Assessment of the formation of interferon neutralizing antibodies and their influence on the effectiveness of interferon therapy in children with juvenile respiratory papillomatosis].
abstract: Formation of neutralizing antibodies (NAB) to alpha-interferon (aINF) was assessed in the reaction of antiviral activity neutralization in 36 children with severe juvenile respiratory papillomatosis (JRP). Surgical removal of papillomas was combined with administration of recombinant aINF preparations (reaferon, intron A, viferon). High and moderate neutralizing activity was determined in 22 (61.1%) patients. 7, 2 and 13 of them received reaferon, intron A and viferon, respectively. NAB were not registered in the rest 14 (38.9%) patients. The frequency of NAB formation was not related to the preparation used, only in the group on reaferon it was insignificantly higher. It was found that the highest response to therapy occurred in children with low NAB titer (8 of 12 children, 66.7%), while children with high NAB titer (3 of 4 children, 75%) did not respond.
authors.forename: R Kh
authors.initials: RKh
authors.lastname: Nurmukhametov
authors.forename: E K
authors.initials: EK
authors.lastname: Onufrieva
authors.forename: Iu L
authors.initials: IuL
authors.lastname: Soldatskiĭ
authors.forename: M V
authors.initials: MV
authors.lastname: Mezentseva
authors.forename: N V
authors.initials: NV
authors.lastname: Kas'ianova
authors.forename: M V
authors.initials: MV
authors.lastname: Tsvetnova
authors.forename: V D
authors.initials: VD
authors.lastname: Kol'tsov
mesh_terms: D000293:Adolescent; D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation; D000998:Antiviral Agents / Q000276:immunology*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology*; D007822:Laryngeal Neoplasms / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D008297:Male; D009500:Neutralization Tests; D010212:Papilloma / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D012120:Respiration Disorders / Q000209:etiology*; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D000998:Antiviral Agents; D016898:Interferon-alpha